newsfilter
← Earnings
Earnings Releases·

Black Diamond Therapeutics — Q3 2026 Earnings Summary

  • Cash and investments declined to $102.0 million as of September 30, 2026, from $128.7 million at year-end 2025, while net loss widened to $10.0 million for the quarter compared to $8.5 million in 2025; accumulated deficit rose to $493.7 million.
  • The company expects its current cash position to fund operations through the second half of 2028 and plans to initiate a global Phase 3 registrational trial for silevertinib in the second quarter of 2027.
  • Updated Phase 2 data for silevertinib in 1L EGFR-NCM NSCLC demonstrated a 60% ORR and 93% DCR, with no new safety signals observed and enrollment ongoing in Cohort 4 at the pivotal 150 mg QD dose.
  • FDA feedback supports a potential accelerated approval pathway based on CNS-ORR and full approval based on PFS, contingent on demonstrating no overall survival detriment compared to the control arm.
  • License revenue was $0 for the quarter ended September 30, 2026, compared to $70.0 million for the same period in 2025, while R&D expenses decreased to $7.0 million and G&A expenses increased to $5.1 million.
Company
BLACK DIAMOND THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology